Brief: Biomea Fusion Announces Bmf-219 Was Generally Well Tolerated, No Dose Reductions, Dose Discontinuations
07/12/2023 16:45
Dec 7 (Reuters) - Biomea Fusion Inc BMEA.O :
* BIOMEA FUSION INC - BMF-219 WAS GENERALLY WELL TOLERATED;
THERE
WERE NO DOSE REDUCTIONS, DOSE DISCONTINUATIONS, OR SEVERE OR
SERIOUS ADVERSE EVENTS
* BIOMEA FUSION INC - BMF-219 DISPLAYED GLUCOSE-CONTROLLED
BETA
CELL PROLIFERATION IN A PRECLINICAL EX-VIVO HUMAN ISLET MODEL,
* BIOMEA FUSION INC - IN EX-VIVO CULTURED ISLETS, BMF-219
IMPROVED
HUMAN BETA-CELL FUNCTION AND PROLIFERATION
* BIOMEA FUSION INC - IN T2D, BMF-219 FOR 4 WEEKS RESULTED
IN
MEANINGFUL HBA1C REDUCTIONS AT TREATMENT COMPLETION (WEEK 4) AND
DURING 26-WEEK FOLLOW-UP
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Biomea Fusion
See all newsUS RESEARCH ROUNDUP-BlackRock, Microsoft, TransDigm Group
Brief: Biomea Fusion Announces Phase 1 Results For Bmf-650, Its Investigational Next-Generation Oral Small Molecule Glp-1 Receptor Agonist
Brief: Biomea Fusion To Announce Phase I Results For Bmf-650, Its Next-Generation Oral Small-Molecule Glp-1 Receptor Agonist
Brief: Biomea Fusion Announces Termination Of Proposed Public Offering Of Securities
Brief: Biomea Fusion Announces Completion Of Enrollment In Covalent-211 Phase Ii Trial Of Icovamenib In Insulin-Deficient Type 2 Diabetes